# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Relay Therapeutics (NASDAQ:RLAY) with a Buy and maintains $20 price ...
The new programs announced today do not change cash guidance, which is expected to fund operations into the second half of 2026.
Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by ...
Barclays analyst Peter Lawson upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and maintains the pr...
JMP Securities analyst Silvan Tuerkcan reiterates Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and maintains $2...
Oppenheimer analyst Matthew Biegler reiterates Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price targe...